Pancreatic tumor sensitivity to plasma L-asparagine starvation

Pancreas

Volumn 41, Issue 6, 2012, Pages 940-948

  Dufour, Emmanuelle ^a   Gay, Fabien ^a   Aguera, Karine ^a   Scoazec, Jean Yves ^b   Horand, Françoise ^a   Lorenzi, Philip L ^c   Godfrin, Yann ^a  

^a ERYTECH PHARMA   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cytotoxicity; immunohistochemistry; L asparaginase; L asparagine synthetase; pancreatic carcinoma; tissue micro array

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; GLUTAMINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ERYTHROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; ERYTHROCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863989495     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318247d903     Document Type: Article

References (21)

1. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol. 2005;15:247Y253.
2. Verma N, Kumar K, Kaur G, et al. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol. 2007;27:45Y62.
3. Schrek R, Dolowy WC, Ammeraal RN. L-asparaginase: toxicity to normal and leukemic human lymphocytes. Science. 1967;155: 329Y330.
4. Horowitz B, Madras BK, Meister A, et al. Asparagine synthetase activity of mouse leukemias. Science. 1968;160:533Y535.
5. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J. 2001;358:59Y67.
6. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357:321Y328.
7. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5:2613Y2623.
8. Lorenzi PL, Llamas J, Gunsior M, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008;7:3123Y3128.
9. Domenech C, Thomas X, Chabaud S, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153:58Y65.
10. Alpar HO, Lewis DA. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem Pharmacol. 1985;34:257Y261.
11. Kravtzoff R, Ropars C, Laguerre M, et al. Erythrocytes as carriers for l-asparaginase. methodological and mouse in-vivo studies. J Pharm Pharmacol. 1990;42:473Y476.
12. Updike SJ, Wakamiya RT, Lightfoot EN Jr. Asparaginase entrapped in red blood cells: action and survival. Science. 1976;193:681Y683.
13. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425Y435.
14. Miller HK, Balis ME. Glutaminase activity of L-asparagine amidohydrolase. Biochem Pharmacol. 1969;18:2225Y2232.
15. Piraud M, Vianey-Saban C, Bourdin C, et al. A new reversed-phase liquid chromatographic/tandem mass spectrometric method for analysis of underivatised amino acids: evaluation for the diagnosis and the management of inherited disorders of amino acid metabolism. Rapid Commun Mass Spectrom. 2005;19:3287Y3297.
16. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272:C1691YC1699.
17. Bourgeaux V, Hequet O, Campion Y, et al. Inositol hexaphosphate-loaded red blood cells prevent in vitro sickling. Transfusion. 2010;50:2176Y2184.
18. Poznansky MJ, Shandling M, Salkie MA, et al. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res. 1982;42:1020Y1025.
19. Wu MC, Arimura GK, Yunis AA. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int J Cancer. 1978;22:728Y733.
20. Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112:4832Y4838.
21. Citri N, Zyk N. Stereospecificity of the catalytic reaction of L-asparaginase. Biochemistry. 1972;11:2103Y2109.